This inventor holds 5 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Cellectis S.a., Cellectis. Active years: 2010-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010-2014
Title: The Innovative Contributions of Patrick Chames
Introduction
Patrick Chames is a prominent inventor based in Paris, France. He has made significant contributions to the field of genome engineering and gene therapy. With a total of five patents to his name, Chames has established himself as a key figure in the scientific community.
Latest Patents
Chames' latest patents include groundbreaking work on the use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues. His patents also cover the application of meganucleases for cleaving DNA in non-human or isolated human cells, which can induce homologous recombination in these cells. This work has important implications for genome engineering and gene therapy. Additionally, he has developed a monomer of an I-CreI meganuclease variant that includes specific mutations in its amino acid sequence, allowing it to bind and cleave DNA target sequences effectively.
Career Highlights
Throughout his career, Patrick Chames has worked with notable companies such as Cellectis S.A. and Cellectis. His innovative research has positioned him as a leader in the field of genetic engineering. His work has not only advanced scientific understanding but has also opened new avenues for therapeutic applications.
Collaborations
Chames has collaborated with esteemed colleagues, including Sylvain Arnould and Jean-Charles Epinat. These partnerships have further enhanced his research and contributed to the success of his projects.
Conclusion
Patrick Chames is a distinguished inventor whose work in genome engineering and gene therapy has made a lasting impact. His innovative patents and collaborations reflect his commitment to advancing scientific knowledge and improving therapeutic techniques.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
